Cardiomyopathy and related heart failure affect millions of Americans. Therefore, pathway-based therapies are highly desirable. The goal of this proposal is to leverage unique genetic tools in zebrafish to elucidate cardioprotective functions of target of rapamycin (TOR) signaling and develop novel therapeutic compounds via modifier screens. There are two obstacles prohibiting modifier screens from being conducted in adult zebrafish: the lack of adult assays to analyze cardiomyopathy-like phenotypes, and the difficulty to track adult mutant fish. To address the former challenge, we established and characterized first adult fish models of cardiomyopathy, including a model induced by Doxorubicin (DOX). To address the latter challenge, we adapted a transposon-based insertional mutagenesis strategy that facilitates the identification of all mutants by a RFP tag. We have conducted both phenotype-based insertional mutagenesis screens and chemical screens, and identified gene modifiers and compound modifiers of TOR signaling that sequentially affect DOX-induced cardiomyopathy. Preliminary studies using these genetic resources suggested that activated autophagy conveys the cardioprotective function of TOR inhibition. In this proposal, we will continue to leverage zebrafish genetics to test our central hypothesis that the cardioprotective functions of TOR inhibition are conferred by the activated autophagy, which can be harnessed by modifier screens in adult zebrafish to identify novel genes and therapeutics for treating cardiomyopathy.
In Specific Aim 1, we will determine the conservation of adult zebrafish as a model organism for cardiomyopathy.
In Specific Aim 2, we will discern functions of autophagy and pS6K subpathways in cardiomyopathy via phenotyping two modifier mutants that differentially affect TOR signaling.
In Specific Aim 3, we plan to discover novel compound modifiers of TOR signaling that could be of greater therapeutic value for cardiomyopathy. At the end of the project, we expect to validate a cardioprotective function of TOR inhibition, to define autophagy as the major downstream signaling branch that confers this cardioprotective function, and to identify compounds that specifically interfere with the TOR-autophagy subpathway that might be of better therapeutic value than rapamycin. Our studies will establish adult zebrafish as a conservative animal model to identify novel modifiers of cardiomyopathy, as well as a complete in vivo model organism to facilitate drug discovery.
This proposal leverages the unique tools in zebrafish to seek TOR signaling-based therapies for cardiomyopathy and heart failure. We aim to use this unique animal model to identify gene modifiers of cardiomyopathy that will elucidate cardioprotective functions of TOR inhibition, and compounds in this pathway with therapeutic value for cardiomyopathy.
|Yang, Jingchun; Shih, Yu-Huan; Xu, Xiaolei (2014) Understanding cardiac sarcomere assembly with zebrafish genetics. Anat Rec (Hoboken) 297:1681-93|
|Campbell, Jarryd M; Hartjes, Katherine A; Nelson, Timothy J et al. (2013) New and TALENted genome engineering toolbox. Circ Res 113:571-87|
|Ding, Yonghe; Liu, Weibin; Deng, Yun et al. (2013) Trapping cardiac recessive mutants via expression-based insertional mutagenesis screening. Circ Res 112:606-17|
|Hoage, Tiffany; Sun, Xiaojing; Xu, Xiaolei (2011) Functions of the Wnt/?-catenin pathway in an anemia-induced zebrafish model of cardiomyopathy are location dependent. Biochem Biophys Res Commun 415:490-6|
|Clark, Karl J; Balciunas, Darius; Pogoda, Hans-Martin et al. (2011) In vivo protein trapping produces a functional expression codex of the vertebrate proteome. Nat Methods 8:506-15|
|Ding, Yonghe; Sun, Xiaojing; Huang, Wei et al. (2011) Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. Circ Res 109:658-69|